![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 45, 32079-32084, November 5, 1999

T Cells*
,
,
,
,
From the Most human blood Although the vast majority of T lymphocytes recognize via their
Structural Analysis of Phosphoantigens--
TUBag1 and TUBag3
were purified from 20 liters of Mycobacterium fortuitum
culture medium using HPLC and HPAEC as described (5). Ion Trap
electrospray ionization mass spectrometry (LCQ, Finnigan Thermoquest,
Les Ulis, France) was done in negative mode with scanning over a mass
range of 100-2000 mass units, and TUBag samples were diluted 1 µg/µl in isopropanol/water (v/v) to which 1% triethylamine had
been added and were introduced by continuous infusion at 3 µl/min.
MSn was done on the specified main ions with a window of 5 mass units using He collisions with 25% total beam energy. Structural
combinations were calculated with Molgen (Molgen Softwares, Bayreuth,
Germany). HPAEC and HPLC were coupled to a photodiode array detector
(Millenium, Waters) scanning at 1 spectrum/s between Bioassays of Human Molecular Masses of TUBag1 and -3--
Thirty µg of pure TUBag3
(UTP The X Moiety Contains a Carbonyl Group--
To screen the 1065 structural options, we synthesized organic PP esters of 262 atomic mass
units (in acidic form) bearing either linear saturated alkyls, polyols,
rings, ketones, or lactones, and we searched for compounds with Rt on
HPAEC matching that of the mycobacterial XPP TUBag1 (5). Only
carbonyl-containing phosphoesters did so (Fig.
2) and presented phosphoantigenic
bioactivity for TUBag1 Is a 3-Formyl-1-butyl-PP--
When their bioactivities for
Together with a primary alcohol and an aldehyde group, these results
establish that the free X alcohol of 102 atomic mass units
phosphorylated in the mycobacterial metabolites TUBag1, 3, and 4 is
3-formyl-1-butanol:
H3C-HC(CHO)-CH2-CH2-OH.
Consequently, based on former structural evidence (5, 6) and the
present findings, the complete structures of mycobacterial
phosphoantigens TUBag1, 3, and 4 can be established as, respectively,
3-formyl-1-butyl-PP, 3-formyl-1-butyl- Structural Determinants of 3-Formyl-1-butyl-PP, Which Affect
The early responses of polyclonal Human V 3-Formyl-1-butyl-PP is a five-carbon molecule of linear structure with
a unique ramification distal from the diphosphorylated hydroxyl.
This type of phosphoester does not correspond to any formerly described
natural compound and, consequently, cannot be strictly assigned to any
known metabolic route. However, two structures resembling five-carbon
phosphodiesters, isopentenyl- and dimethylallyl-PP, are ubiquitous
precursors for steroids and isoprenoids. Although in most cells, such
compounds come from acetyl coenzyme A and mevalonate, in algae and in
several eubacterium including Corynebacterium and
Mycobacterium (17), their biosynthesis proceeds by a
separate route that has been discovered recently (18, 19). This latter,
referred to as the Rohmer's or DXP (1-deoxy-D-xylulose-5-phosphate) pathway, arises from the
decarboxylate condensation of glyceraldehyde 3-phosphate and pyruvate
(summarized in Fig. 5) by a transketolase
enzyme called DXP synthase, into deoxyxylulose 5-phosphate, which is in
turn converted by a DXP reductoisomerase into
2-C-methyl-D-erythritol-4-phosphate, a linear trihydroxylated five-carbon molecule with a unique CC ramification distal from the diphosphorylated hydroxyl. This triol monophosphate has
been found in several bacteria and is assumed to lead to isopentenyl-PP biosynthesis through several yet-unidentified reducing and
phosphorylating steps. Its highly relevant structure, harboring both an
oxidation level intermediate between
2-C-methyl-D-erythritol and isopentenyl and a lower
phosphorylation suggests that the mycobacterial 3-formyl-1-butyl-PP clearly constitutes one of such late C5-PP intermediates
(17-19). In this sense, although natural 3-formyl-1-butyl-PP had not
been described yet, it appears an ideal candidate precursor of
mycobacterial prenyl phosphates biosynthesis by Rohmer's pathway.
By targeting their reactivity toward the mevalonate-independent pathway
of isoprenoid biosynthesis proper to mycobacteria and to some other
eubacteria, human We are grateful to Dr. M. M. Daffé
for helpful reviewing of the manuscript.
*
This study was supported by institutional grants from
INSERM, Aide aux Programme Exceptionnels (to J-J. F.), SangStat
Medical Corporation (to C. B.), Association pour la Recherche sur le
Cancer 9754 (to J-J. F.), la Fondation pour la Recherche
Médicale, la Région Midi-Pyrénées, and World
Health Organization United Nations Developmental Program-Global Program
for Vaccines (V25/181/179).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
2
Craig Morita, personal communication.
The abbreviations used are:
TCR, T cell
receptor;
DXP, 1-deoxy-D-xylulose-5-phosphate;
MSn, multiple stages mass spectrometry;
HPLC, high
performance liquid chromatography;
HPAEC, high pH anion exchange
chromatography;
PP, pyrophosphate;
IPP, isopentenyl-PP;
PPi, inorganic PP;
m, multiplet;
TUBag, Mycobacterium
tuberculosis antigens;
V, variable;
Rt, retention time.
INSERM U395,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

T cells react without
major histocompatibility complex restriction to small phosphorylated
nonpeptide antigens (phosphoantigens) that are abundantly produced by
mycobacteria and several other microbial pathogens. Although
isopentenyl pyrophosphate has been identified as a mycobacterial
antigen for 
T cells, the structure of several other stimulating
compounds with bioactivities around 1000-fold higher than isopentenyl
pyrophosphate remains to be elucidated. This paper describes the
structural identification of 3-formyl-1-butyl-pyrophosphate as the core
of several non-prenyl mycobacterial phosphoantigens bioactive at the
nM range. Recognition of this molecule by 
T
cells is very selective and relies on its aldehyde and pyrophosphate
groups. This novel pyrophosphorylated aldehyde most probably
corresponds to a metabolic intermediate of the non-mevalonate pathway
of prenyl phosphate biosynthesis in eubacteria and algae. The
reactivity to 3-formyl-1-butyl-pyrophosphate supports the view that
human 
T cells are physiologically devoted to antimicrobial surveillance.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

TCR1 antigenic
peptides associated to major histocompatibility complex molecules, the
so-called unconventional T cells that often express 
TCR
recognize their ligands in a different way. The prominent 
T cell
subset in human blood expresses the V
9/V
2 TCR and responds to
nonpeptide antigens produced by various microbial pathogens, such as
mycobacteria. The mycobacterial stimuli for these T cells have been
characterized independently by two groups as nonpeptide phosphoesters,
collectively referred to as phosphoantigens. On the one hand,
isoprenoid-PP such as isopentenyl-PP, dimethylallyl-PP, farnesyl-PP,
and geranyl-PP have been characterized as V
9/V
2 T
cell-stimulating ligands in bioactive fractions from mycobacteria (1-4). On the other hand, we have purified from several mycobacterial species a set of four phosphoantigens composed of two pyrophosphates of
an unidentified monoester (X, in the so-called TUBag1 and TUBag2) and
of the corresponding X-phosphodiesters of
-UTP (5) and
-TTP (6)
(respectively, TUBag3 and TUBag4). These TUBag compounds have been
shown to be active at the nM range (i.e. with
bioactivities about 1000-fold higher than that of IPP), thus suggesting
that these molecules could account for most of the 
T
cell-stimulating activity recovered from mycobacteria. Poor yields and
intrinsic lability of purified TUBag1-4 have considerably slowed the
identification of X. However, several biochemical lines of evidence
indicated that this mycobacterial X moiety was distinct from prenyl
phosphates (5, 7). Accordingly, a molecular analysis of phosphoantigen recognition has evidenced a pattern of TCR 
cell reactivity that
distinguishes alkyl-PP from mycobacterial phosphoantigens (8). To
understand the fine specificity of 
T cell reactivity to
mycobacteria, we have identified the hitherto referred-to X moiety as
3-formyl-1-butyl-PP. The activation of 
T cells by this
non-prenyl phosphoantigen resembling and most likely related to
isopentenyl-PP is due to the efficient perception of its aldehyde and
PP segments. Hence, the stringent property of human 
T cells to
recognize very rapidly and without major histocompatibility complex
restriction low concentrations of phosphoantigens sheds light on
their immune role in microbial surveillance.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
200 and 800 nm
with a 0.5 nm window. Chemical synthesis of pyrophosphate esters and of
UTP-
-esters was achieved by nucleophilic displacement of tosylated alcohols with pyrophosphate or reaction of the corresponding alcohols with carbodiimide-activated UTP as described (9-11). The structures of
the compounds were checked by MSn, 1H NMR and
HPAEC. Chemical treatments of isopentenyl-PP, 2-butanone-1-yl-PP, and 3-formyl-1-butyl-PP (TUBag1) were done as follows. Samples were added to 5 mM NaIO4 (Aldrich) (total
volume of 100 µl (pH 7)) for 35 min at room temperature and 25 min at
4 °C, and further neutralization of excess NaIO4 before
cell assays was done by the addition of a few drops of glycerol to the
sample. Reduction was performed by adding 100 µl of 10 mM
NaBH4 (Aldrich) containing 4 mM
NH4OH for 40 min at room temperature, followed by
neutralization with 5 µl of methanol. Similar conditions were applied
with NaBH3CN (10 mM) in phosphate buffer, pH
7.3. KMnO4 was used at 1 mM, pH 7 for 30 min at
4 °C and neutralized by 3 µl of aqueous isopentenol; MnO2 precipitate was pelleted by centrifugation (5 min at
10 °C), and the supernatant was assayed. Aqueous bromine treatment
was done according to Belmant et al. (10) with modification
using a 1:10 dilution of a 1.5 mM Br2 aqueous
stock solution (15 min at 4 °C, pH 6).

T Cell Activation--
Bioactivities
of the specified molecules were drawn from the titration of the
autocytotoxic response of a V
9/V
2 T cell clone stimulated by
serial dilutions of the phosphoantigens (12). The ability of the
molecules to trigger selective expansion of V
9/V
2 peripheral
blood lymphocytes in short term culture assays was assessed as
described previously (12). Briefly, peripheral blood lymphocytes from
healthy donors were cultured for 8 days with the specified molecules in
culture medium supplemented with recombinant human interleukin 2, and
the frequency of CD3+ V
2+ cells (monoclonal
antibodies from Coulter-Immunotech, Marseille, France) was estimated by
flow cytometry using a FACScan apparatus (Becton Dickinson, Mountain
View, CA). Polyclonal V
9/V
2 T cells stimulated by untreated or
NaBH4-treated phosphoantigens were analyzed using a
microphysiometer (Cytosensor, Molecular Devices, Crawley, UK), with
8 × 105 cells/experiment, a flow (100 µl/min) of
low-buffered RPMI (Molecular Devices, Crawley, UK) alone (Fig. 4,
control lanes) or containing the specified stimulus
(added at a time shown by arrow), and data collection rate
of 90 s.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-X) molecule obtained as described (5) were analyzed by Ion Trap
electrospray ionization-MS in negative mode (Fig.
1A). The spectrum showed
abundant ions at m/z 567 and
m/z 589, corresponding to (M-H)
and
(M+Na-2H)
, respectively. This result unambiguously
indicates a molecular mass of 568 atomic mass units for TUBag3,
i.e. 84 atomic mass units above that of UTP. Subsequent
negative MS2 from m/z 567 (Fig.
1B) yielded the fragments (UTP-H)
,
(UDP-H)
, and (UMP-H)
, demonstrating the
UTP
-X structure formerly assigned to TUBag3 (5). Most importantly,
this negative MS2 spectrum showed fragments at
m/z 261 and m/z 243, corresponding to the (XPP-H)
fragment and its anhydro
derivative (XPP-H2O-H)
. Thus, X-OH has a
molecular mass of 102, and the PP monoester which corresponds to TUBag1
(6), has a molecular mass of 262 atomic mass units, confirming a recent
observation (13). This conclusion was supported by negative
MS3 from m/z 261, which yielded an
anhydro fragment (m/z 243) and two diagnostic
fragments corresponding to a ketene (CH2=CO) loss (m/z 219) and a PPi fragment
(m/z 159, Fig. 1C). Moreover, these data indicate the presence of a carbonyl group in XPP and establish the
structure of the PP monoester. This negative MS3 spectrum
from TUBag3 was identical to the negative MS2 spectrum from
ions at m/z 261 observed in the negative
MS1 spectrum from TUBag1, obtained in similar conditions as
in Fig. 1A (data not shown). No anion was generated from
X-OH in these experiments, so this molecule presumably contains few
oxygen atoms and no carboxylic group. Furthermore, its even mass
indicates either an absence of the N atom or the presence of an even
number of N atoms. With a general formula C1-7,
Hn, O1-4, N2-or-4, 21,533 isomeric
structures correspond to a molecular mass of 102 atomic mass units,
among which only 1065 are noncarboxylic with at least one primary
alcohol as the phosphorylation site.

View larger version (30K):
[in a new window]
Fig. 1.
Ion Trap electrospray ionization mass
spectrometry of mycobacterial phosphoantigens. The postulated
structures for TUBag3 and its MS fragments are shown above.
A, negative MS1 of TUBag3, infusion of 3 µg/min in isopropanol/water/triethylamine (50/50/1); B,
negative MS2 of the TUBag3 pseudomolecular ion
m/z 567 selected in A and shown by an
arrow; C, negative MS3 of ion
m/z 261 selected from B and shown by
an arrow.

T cell clones, although in the micromolar range,
as already found with prenyl-PP (1). Since similar results were
obtained with the UTP-
-ester analogues when compared with the
mycobacterial X-UTP (TUBag3); these data suggest the presence of a
carbonyl group in X. This assumption was confirmed by spectroscopy.
First, a Fourier transform infrared spectrum of TUBag1 (5 µg) in
water presented a C=O stretching band at 1670 cm
1
(versus 1700 cm
1 for a synthetic ketone-PP
reference; not shown). Second, based on the weak
of C=O at
260-300 nm in UV (
max < 30 M
1.cm
1), a photodiode array
comparison of HPLC-purified TUBag1 to relevant standards (Fig.
3) evidenced a weak absorption at
max between 265 and 268.6 nm. Similar data were obtained
with synthetic hydroxyketones standards, whereas conversely, PP, IPP,
or pentanol do not absorb in this range. Thus, in agreement with the
ketene loss from X-PP observed in the negative MS3
fragmentation (Fig. 1C), X contains a noncarboxylic C=O
group whose local charge (
0.3) accounts for its peculiar HPAEC
Rt.

View larger version (15K):
[in a new window]
Fig. 2.
Comparative HPAEC analysis of various
alkyl-PP to TUBag1 and TUBag3. The specified molecules were
analyzed on a DX500 HPAEC apparatus as already described (7) and
compared with inorganic phosphate, PPi, TUBag1, and TUBag3
references. For clarity, the eluting positions of the above-specified
compounds have been indicated by arrows. Note that
butanone-1-yl-PP and butanone-1-yl-UTP present the same Rt as TUBag1
and TUBag3, respectively. µS, microsiemens.

View larger version (31K):
[in a new window]
Fig. 3.
Spectroscopic analysis of
3-formyl-1-butyl-PP. Top, comparative photodiode array
absorption in the
200-300-nm region showing absorption
(Abs) due to the carbonyl of HPLC-purified TUBag1 (6) in
water solvent and spectra recorded in the same conditions of the
following references: 1, 3-methyl-1-pentanol; 2,
PP; 3, isopentenyl-PP; 4,
1-hydroxy-2-methyl-3-butanone; 5, 1-hydroxy-4-pentanone. The
observed
max from the 250-300-nm region, with 0.5-nm
precision are given above. Bottom, structure of
3-formyl-1-butyl-PP and its NMR attributions collected from previous
TUBag3 and TUBag4 spectral data (5, 6, 15).

T cells were titrated by serial dilutions, mycobacterial
phosphoantigens were stimulatory at nanomolar concentrations (5).
However, synthetic keto-pyrophosphoesters or UTP-
-esters such as
2-butanone-1-yl-PP, 3-pentanone-1-yl-PP, 4-pentanone-1-yl-PP, or
2-methyl-3-butanone-1yl-(or 2-yl-)-
-UTP had much weaker (5-80
µM) phosphoantigenic bioactivities. Therefore, we
compared the functional group of mycobacterial X-PP to that of a
synthetic keto-pyrophosphoester reference by titrating their bioactivities after selective chemical treatments (Table
I). The bioactivities of untreated TUBag1
(5 nM), 2-butanone-1-yl-PP (30 µM), and
isopentenyl-PP (3 µM) were unaffected by treatment with 5 mM NaIO4, pH 7. On the contrary, TUBag1 (or
whole mycobacterial extract), but not IPP (nor any prenyl phosphate),
was totally inactivated by reduction with 10 mM
NaBH4, as expected for carbonyls (see 2-butanone-1-yl-PP in
Table I). Furthermore, bioactivity of TUBag1 (or that of whole
mycobacterial extract) was also totally abrogated by oxidation with 1 mM KMnO4, a treatment that did not affect
bioactivity of IPP, prenyl phosphates, or 2-butanone-1-yl-PP (Table I).
These data clearly demonstrate that mycobacterial phosphoantigens are
different from prenyl phosphates. IPP oxidation by KMnO4
produced the diol-PP,
CH2OH-C(CH3)OH-CH2-CH2-O-PP,
with a molecular mass of 280 atomic mass units, an HPAEC Rt identical to that of TUBag1, and a phosphoantigenic bioactivity similar to that
of IPP (3-5 µM in autocytotoxic response of a
V
9/V
2 T cell clone, not shown). The bioactivity of
KMnO4-oxidized IPP is due to the
C3-C4 diol moiety, as this latter was
chemically converted by 5 mM NaIO4 into
3-butanone-1-yl-PP (same HPAEC Rt as TUBag1, bioactivity 50-80
µM), an unstable compound prone to
elimination into
1-buten-3-one (HPAEC Rt = 0 min, biologically inactive) and PPi.
The low bioactivity of C3-C4 diol suggests that
dihydroxylated phosphoantigens are unlikely to be the natural antigens.
Thus, TUBag1 contains a primary alcohol (phosphorylation site) and a
carbonyl (reduced by NaBH4 and oxidized by
KMnO4). TUBag1 does not contain any imine group
(C=N), as it was resisted to treatment with 10 mM
NaBH3CN at neutral pH (14). To check for the presence of
HC=O or of enol, TUBag1 and IPP were treated by cold bromine water (0.5 mM, pH 6), which adds double bonds or readily oxidizes
aldehydes with
-H. Br2-treated IPP remained bioactive,
indicating that this treatment did not degrade the phosphate bonds and
that unsaturation was not mandatory for bioactivity. Conversely, the
bioactivity of Br2-treated TUBag1 was completely abolished
(Table I), implying the presence of an aldehyde that was either
oxidized by aqueous Br2 and KMnO4 or reduced by
NaBH4 into distinct inactive molecules. In agreement with
the above spectroscopic data and MS fragmentation pattern of TUBag1,
this conclusion was further supported by a weak positive Schiff
staining of concentrated HPLC fractions of TUBag1. Previous data from
NMR analysis of TUBag3 (5) and TUBag4 (6) completed this
identification. In both 1H spectra from TUBag4 or TUBag3,
two primary alcohol protons (-CH2-O-P-) were detected at
4.10 ppm (m) and 4.20 ppm (m), respectively. These protons coupled
together (J = 15 Hz) and to two adjacent methylenic
(-CH2-CH2-O-P-) protons at 3.47 ppm and 3.57 ppm in TUBag3 and at 3.49 ppm and 3.58 ppm in TUBag4, indicating the presence of a dimethylene group in both antigens. In addition, a well
defined 1H-1H coupling was observed in TUBag4
between the protons at 1.26 ppm (3H, J = 7.6 Hz, Me)
and 4.10 ppm (1H), which implies a H3C-CH- group, which was
confirmed by 1H-13C homonuclear multiple
quantum and homonuclear multiple bond correlation spectroscopy
experiments (CMe: 22 ppm; CH: 65 or 75 ppm
(15)).
Phosphoantigen bioactivity after chemical treatment
9/V
2 T cell clone stimulated by serial dilutions of samples in
three to five independent experiments. Untreated bioactive sample
concentrations are: IPP, 3 µM 2-butanone-1-yl-PP, 80 µM. Mycobacterial TUBag1 bioactivity was tested at up to
a 1:1000 dilution, corresponding to 5-10 µM TUBag1
(7). +, bioactive molecule;
, abrogation of bioactivity;
nt, not
tested.
-UTP, and
3-formyl-1-butyl-
-TTP. No fully convincing MS of TUBag2 could be
obtained. Nevertheless, its slightly higher Rt on C18 HPLC
(6) and on HPAEC (7) and the preliminary report of a mycobacterial
aldehydic2 phosphoantigen of
mass 276 (8) suggest that TUBag2 corresponds to a closely related
longer chain homolog of TUBag1 such as 3-formyl-1-pentyl-PP.

T Cell Reactivity--
Reactivity of human 
T cells to
phosphoantigens is not strictly selective, because various
phosphoesters comprising a linear C2 core as ethyl-PP are
stimulatory, although at nearly 103 times higher
concentrations (EC50% = 10-30 µM). Since
isoamyl-PP (the saturated analogue of IPP) does not activate 
T
cells, the relatively higher bioactivity of isopentenyl-PP
(EC50% = 1-3 µM) has been attributed to its
prenylic unsaturation (1). This olefin is better recognized than its
related C3-C4 diol-PP (see KMnO4-treated IPP in Table I, EC50% = 10 µM) and than the subsequent C3-carbonyl
derivative (NaIO4 oxidized C3-C4
diol-PP: EC50% = 50-80 µM, data not shown).
Similarly, the potent activity of 3-formyl-1-butyl-PP on human 
T
cells (5-10 nM range (5)) is clearly conferred by its
aldehyde group. Although NaBH4 reduction of
3-formyl-1-butyl-PP changed slightly, its topology (increasing the
antigen volume from 179 Å3 to 183 Å3 and
lowering the local dipolarity at C4 from 2.2 to 1.4 Debye), this subtle structural alteration totally abrogated the bioactivity of
this compound (Table I and Fig. 4).
Activation of human 
T cells by mycobacterial ligands such as the
purified 3-formyl-1-butyl-PP induced a powerful in vitro
expansion of V
9/V
2 T cells from peripheral blood lymphocytes of
healthy donors, whereas the topologically resembling
NaBH4-reduced 3-formyl-1-butyl PP did not (Fig. 4, upper panel). T cell proliferation is, however, a late
event, usually detected after several days of in vitro
cultures stimulated from the beginning of the assay. Hence, the 
cell unresponsiveness to NaBH4-reduced 3-formyl-1-butyl-PP
could possibly reflect the capacity of this compound to inhibit late
steps of cell proliferation without actually interfering with its
initial recognition by T cells. We assayed whether early steps of

T cell activation by TUBag1 were also crucially determined by
its aldehyde function.

View larger version (29K):
[in a new window]
Fig. 4.
Recognition of 3-formyl-1-butyl-PP but not of
its NaBH4-reduced derivative activates human

T cells.
Upper, in vitro expansion of 
T cells in
polyclonal lymphocyte cultures in complete culture medium for 1 week in
the presence of interleukin 2 and stimulated as formerly described (6)
by no phosphoantigen (A), 100 nM
3-formyl-1-butyl-PP (B), or 100 nM
NaBH4-reduced product (C). Lower, the
microphysiometric response of polyclonal 
T cells to the same
stimuli (A, B, C) as above was monitored by Cytosensor
(Molecular Devices) as described under "Experimental Procedures,"
with the stimuli added at time 0.

T cell lines to
3-formyl-1-butyl-PP and to its NaBH4-reduced derivative
were compared using a microphysiometer monitoring the acidification
rate of culture media (16). We recorded a rapid cell response to
mycobacterial 3-formyl-1-butyl-PP and found that its
aldehyde-to-alcohol reduction abrogated its bioactivity (Fig. 4,
lower panel). These experiments confirmed that the 
T
lymphocyte unresponsiveness to reduced antigen is due to abrogation of
early events leading to cell activation such as antigen recognition.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
9/V
2 T cells predominate in adult blood but not in
thymus (20-23). This age-related peripheral bias most likely reflects a chronic exposure to highly recurrent ligands (24). Accordingly, the
broad reactivity of V
9/V
2 T cells to various microbial, viral,
and protozoan pathogens arises from their unique ability to
specifically recognize a peculiar set of natural
nonpeptide-phosphorylated ligands called phosphoantigens (2, 13, 25).
Several structurally different phosphoantigens occur in nature
(26-28), and in particular, microbial pathogens that infect humans and
primates show a marked tendency to synthesize such metabolites (25).
Here we found that several mycobacterial phosphoantigens comprise a
3-formyl-1-butyl-PP moiety, either alone, like the formerly described
TUBag1 antigen, or as a nucleotide conjugate like the
-phosphodiester of 5'-UMP and 5'-TMP in TUBag3 and TUBag4,
respectively. Furthermore, we found that the 
cell-mediated
recognition of such mycobacterial 3-formyl-1-butyl-PP ligand involves
determinants defined by the PP, as described previously (5-7, 15), but
also by the aldehyde group elucidated in this study (Fig. 4).
Interestingly, this single antigen specificity is recovered in a
polyclonal 
T cell population drawn from distinct healthy
individuals, which confirms several earlier reports about the lack of
major histocompatibility complex restriction and limited bias of TCR
repertoire of such a T cell recognition pattern (3, 4, 30, 31). The
polyclonal specificity for the aldehyde motif is, however, very
selective, as NaBH4 reduction induces a slight change to
the topology of the antigen while abrogating its recognition, a
conclusion fully consistent with the recent finding that the TCR J
region determines subtle changes in phosphoantigen selectivity (8).
Thus, the physiological recognition of mycobacterial phosphoantigens
(i.e. at nanomolar concentrations) is actually a highly
selective process for detecting a defined, although widespread, set of
target cells that secrete these ligands.

View larger version (21K):
[in a new window]
Fig. 5.
Structural similarities of the metabolic
intermediates from the non-mevalonate pathway of isopentenyl-PP
biosynthesis with 3-formyl-1-butyl-PP (inset).
The non-mevalonate pathway metabolites and enzymes are drawn according
to Refs. 29, 32, 33. TPP, thiamine pyrophosphate.

T cells are enabled to detect very low amounts
of proliferating pathogens that secrete such compounds in their
environment (5). This antigen targeting brings a double advantage.
First, it allows the immune system to avoid a permanent activation by
prenyl phosphates, since these latter are ubiquitous metabolites found
in all living cells, including the 
T lymphocytes themselves.
Second, the non-mevalonate pathway has been reported so far only in
eubacteria, fungi, and algae, representing, therefore, a highly
selective target for a suitably focused immune surveillance by T cells
that do not use major histocompatibility complex presentation to
initiate their function. It is likely that related 
T
lymphocyte-stimulating metabolites will be discovered in other
microbial pathogens and plants.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
To whom correspondence should be addressed. Tel.:
335-6274-8364; Fax: 335-6274-8386; E-mail:
fournie@purpan.inserm.fr.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Tanaka, Y.,
Morita, C. T.,
Tanaka, Y.,
Nieves, E.,
Brenner, M. B.,
and Bloom, B. R.
(1995)
Nature
375,
155-158[CrossRef][Medline]
[Order article via Infotrieve]
2.
Tanaka, Y.,
Brenner, M. B.,
Bloom, B. R.,
and Morita, C. T.
(1996)
J. Mol. Med.
74,
223-231[CrossRef][Medline]
[Order article via Infotrieve]
3.
Morita, C. T.,
Beckman, E. M.,
Bukowski, J. F.,
Tanaka, Y.,
Band, H.,
Bloom, B. R.,
Golan, D. E.,
and Brenner, M. B.
(1995)
Immunity
3,
495-507[CrossRef][Medline]
[Order article via Infotrieve]
4.
Tanaka, Y.,
Sano, S.,
Nieves, E.,
De Libero, G.,
Rosa, D.,
Modlin, R. L.,
Brenner, M. B.,
Bloom, B. R.,
and Morita, C. T.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
8175-8179 5.
Poquet, Y.,
Constant, P.,
Halary, F.,
Peyrat, M. A.,
Gilleron, M.,
Davodeau, F.,
Bonneville, M.,
and Fournié, J. J.
(1996)
Eur. J. Immunol.
26,
2344-2349[Medline]
[Order article via Infotrieve]
6.
Constant, P.,
Davodeau, F.,
Peyrat, M. A.,
Poquet, Y.,
Puzo, G.,
Bonneville, M.,
and Fournié, J. J.
(1994)
Science
264,
267-270 7.
Poquet, Y.,
Constant, P.,
Peyrat, M. A.,
Poupot, R.,
Halary, F.,
Bonneville, M.,
and Fournié, J. J.
(1996)
Anal. Biochem.
243,
119-126[CrossRef][Medline]
[Order article via Infotrieve]
8.
Bukowski, J. F.,
Morita, C. T.,
Bloom, B. R.,
and Brenner, M. B.
(1998)
J. Immunol.
161,
286-293 9.
Belmant, C.,
Bonneville, M.,
Fournié, J. J.,
and Peyrat, M. A.
(1998)
Nouveaux Composés Phosphohalohydrines, Procédé de Fabrication et Applications
, INSERM Patent, Ed. INPI, Paris, France
10.
Belmant, C.,
Bonneville, M.,
Fournié, J. J.,
and Peyrat, M. A.
(1998)
Nouveaux Composés Phosphoépoxydes, Procédé de Fabrication et Applications
, INSERM Patent, Ed. INPI, Paris, France
11.
Davisson, D. J.,
Woodside, A. B.,
Neal, T. R.,
Stremler, K. E.,
Muehlbacher, M.,
and Dale Poulter, C.
(1986)
J. Org. Chem.
51,
4768-4779[CrossRef]
12.
Halary, F.,
Peyrat, M. A.,
Champagne, E.,
Lopez-Botet, M.,
Moretta, A.,
Moretta, L.,
Vié, H.,
Fournié, J. J.,
and Bonneville, M.
(1997)
Eur. J. Immunol.
27,
2812-2821[Medline]
[Order article via Infotrieve]
13.
De Libero, G.
(1997)
Immunol. Today
18,
22-26[Medline]
[Order article via Infotrieve]
14.
Borch, R. F.,
Bernstein, M. D.,
and Dupont-Durst, H.
(1971)
J. Am. Chem. Soc.
93,
2897-2904[CrossRef]
15.
Constant, P.
(1995)
Caractérisation Structurale et Fonctionnelle d'Antigènes Mycobactériens Stimulant les T Lymphocyctes Gamma/Delta HumansPh.D. thesis
, p. 168, Université Paul Sabatier, Toulouse, France
16.
Nag, B.,
Wada, H. G.,
Fok, K. S.,
Green, D. J.,
Sharma, S. D.,
Clark, B. R.,
Parce, J. W.,
and McConnell, H. M.
(1992)
J. Immunol.
148,
2040-2044[Abstract]
17.
Rosa Putra, S.,
Disch, A.,
Bravo, J. M.,
and Rohmer, M.
(1997)
Isoprenoid Biosynthesis Regulation and Biotechnological Applications
, Institut de Biologie Moléculaire at d'Ingeniérie Génétique, University of Poitiers, France
18.
Rohmer, M.,
Seeman, M.,
Horbach, S.,
Bringer-Meyer, S.,
and Sahm, H.
(1996)
J. Am. Chem. Soc.
118,
2564-2566[CrossRef]
19.
Rohmer, M.,
Knani, M.,
Simonin, P.,
Sutter, B.,
and Sahm, H.
(1993)
Biochem. J.
295,
517-524
20.
Parker, C. M.,
Groh, V.,
Band, H.,
Porcelli, S. A.,
Morita, C.,
Fabbi, M.,
Glass, D.,
Strominger, J. L.,
and Brenner, M. B.
(1990)
J. Exp. Med.
171,
1597-1612 21.
Mingari, M. C.,
Varese, P.,
Bottino, C.,
Tambussi, G.,
and Moretta, L.
(1989)
Int. J. Cancer
4 (suppl.),
39-42
22.
Casorati, G.,
De Libero, G.,
Lanzavecchia, A.,
and Migone, N.
(1989)
J. Exp. Med.
170,
1521-1535 23.
Giachino, C.,
Granziero, L.,
Modena, V.,
Maiocco, V.,
Lomater, C.,
Fantini, F.,
Lanzavecchia, A.,
and Migone, N.
(1994)
Eur. J. Immunol.
24,
1914-1918[Medline]
[Order article via Infotrieve]
24.
De Libero, G.,
Casorati, G.,
Migone, N.,
and Lanzavecchia, A.
(1991)
Curr. Top. Microbiol. Immunol.
173,
235-238[Medline]
[Order article via Infotrieve]
25.
Fournié, J. J.,
and Bonneville, M.
(1996)
Res. Immunol.
147,
338-346[CrossRef][Medline]
[Order article via Infotrieve]
26.
Burk, M. R.,
Mori, L.,
and De Libero, G.
(1995)
Eur. J. Immunol.
25,
2052-2058[Medline]
[Order article via Infotrieve]
27.
Fischer, S.,
Scheffler, A.,
and Kabelitz, D.
(1996)
Immunol. Lett.
52,
69-72[CrossRef][Medline]
[Order article via Infotrieve]
28.
Holoshitz, J.,
Romzek, N. C.,
Jia, Y.,
Wagner, L.,
Vila, L. M.,
Chen, S. J.,
Wilson, J. M.,
and Karp, D. R.
(1993)
Int. Immunol.
5,
1437-1443 29.
Takahashi, S.,
Kuzuyama, T.,
Watanabe, H.,
and Seto, H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9879-9884 30.
Lang, F.,
Peyrat, M. A.,
Constant, P.,
Davodeau, F.,
David-Ameline, J.,
Poquet, Y.,
Vie, H.,
Fournié, J. J.,
and Bonneville, M.
(1995)
J. Immunol.
154,
5986-5994[Abstract]
31.
Boullier, S.,
Poquet, Y.,
Halary, F.,
Bonneville, M.,
Fournié, J. J.,
and Gougeon, M. L.
(1998)
Eur. J. Immunol.
28,
1-12[CrossRef][Medline]
[Order article via Infotrieve]
32.
Sprenger, G. A.,
Schorken, U.,
Wiegert, T.,
Grolle, S.,
De Graaf, A. A.,
Taylor, S. V.,
Begley, T. P.,
Bringer-Meyer, S.,
and Sahm, H.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12857-12862 33.
Lois, L. M.,
Campos, N.,
Putra, S. R.,
Danielsen, K.,
Rohmer, M.,
and Boronat, A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2105-2110
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
This article has been cited by other articles:
![]() |
K.-J. Puan, C. Jin, H. Wang, G. Sarikonda, A. M. Raker, H. K. Lee, M. I. Samuelson, E. Marker-Hermann, L. Pasa-Tolic, E. Nieves, et al. Preferential recognition of a microbial metabolite by human V{gamma}2V{delta}2 T cells Int. Immunol., May 1, 2007; 19(5): 657 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Caccamo, L. Battistini, M. Bonneville, F. Poccia, J. J. Fournie, S. Meraviglia, G. Borsellino, R. A. Kroczek, C. La Mendola, E. Scotet, et al. CXCR5 Identifies a Subset of V{gamma}9V{delta}2 T Cells which Secrete IL-4 and IL-10 and Help B Cells for Antibody Production J. Immunol., October 15, 2006; 177(8): 5290 - 5295. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Thompson and M. J. Rogers Bisphosphonates and {gamma}{delta} T-Cells: New Insights into Old Drugs IBMS BoneKEy, August 1, 2006; 3(8): 5 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Thompson, J. Rojas-Navea, and M. J. Rogers Alkylamines cause V{gamma}9V{delta}2 T-cell activation and proliferation by inhibiting the mevalonate pathway Blood, January 15, 2006; 107(2): 651 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Corvaisier, A. Moreau-Aubry, E. Diez, J. Bennouna, J.-F. Mosnier, E. Scotet, M. Bonneville, and F. Jotereau V{gamma}9V{delta}2 T Cell Response to Colon Carcinoma Cells J. Immunol., October 15, 2005; 175(8): 5481 - 5488. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kabelitz, D. Wesch, E. Pitters, and M. Zoller Characterization of Tumor Reactivity of Human V{gamma}9V{delta}2 {gamma}{delta} T Cells In Vitro and in SCID Mice In Vivo J. Immunol., December 1, 2004; 173(11): 6767 - 6776. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Favier, E. Espinosa, J. Tabiasco, C. Dos Santos, M. Bonneville, S. Valitutti, and J.-J. Fournie Uncoupling between Immunological Synapse Formation and Functional Outcome in Human {gamma}{delta} T Lymphocytes J. Immunol., November 15, 2003; 171(10): 5027 - 5033. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dieli, F. Poccia, M. Lipp, G. Sireci, N. Caccamo, C. Di Sano, and A. Salerno Differentiation of Effector/Memory V{delta}2 T Cells and Migratory Routes in Lymph Nodes or Inflammatory Sites J. Exp. Med., August 4, 2003; 198(3): 391 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kato, Y. Tanaka, H. Tanaka, S. Yamashita, and N. Minato Requirement of Species-Specific Interactions for the Activation of Human {gamma}{delta} T Cells by Pamidronate J. Immunol., April 1, 2003; 170(7): 3608 - 3613. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori, and G. De Libero Human T Cell Receptor {gamma}{delta} Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells J. Exp. Med., January 20, 2003; 197(2): 163 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Rojas, M. Torres, J.-J. Fournie, C. V. Harding, and W. H. Boom Phosphoantigen Presentation by Macrophages to Mycobacterium tuberculosis-Reactive V{gamma}9V{delta}2+ T Cells: Modulation by Chloroquine Infect. Immun., August 1, 2002; 70(8): 4019 - 4027. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Glatzel, D. Wesch, F. Schiemann, E. Brandt, O. Janssen, and D. Kabelitz Patterns of Chemokine Receptor Expression on Peripheral Blood {gamma}{delta} T Lymphocytes: Strong Expression of CCR5 Is a Selective Feature of V{delta}2/V{gamma}9 {gamma}{delta} T Cells J. Immunol., May 15, 2002; 168(10): 4920 - 4929. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Feurle, E. Espinosa, S. Eckstein, F. Pont, V. Kunzmann, J.-J. Fournie, M. Herderich, and M. Wilhelm Escherichia coli Produces Phosphoantigens Activating Human gamma delta T Cells J. Biol. Chem., January 4, 2002; 277(1): 148 - 154. [Abstract] [Full Text] |
||||
![]() |
F. Miyagawa, Y. Tanaka, S. Yamashita, B. Mikami, K. Danno, M. Uehara, and N. Minato Essential Contribution of Germline-Encoded Lysine Residues in J{gamma}1.2 Segment to the Recognition of Nonpeptide Antigens by Human {gamma}{delta} T Cells J. Immunol., December 15, 2001; 167(12): 6773 - 6779. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Daubenberger, M. Salomon, W. Vecino, B. Hubner, H. Troll, R. Rodriques, M. E. Patarroyo, and G. Pluschke Functional and Structural Similarity of V{gamma}9V{delta}2 T Cells in Humans and Aotus Monkeys, a Primate Infection Model for Plasmodium falciparum Malaria J. Immunol., December 1, 2001; 167(11): 6421 - 6430. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kato, Y. Tanaka, F. Miyagawa, S. Yamashita, and N. Minato Targeting of Tumor Cells for Human {gamma}{delta} T Cells by Nonpeptide Antigens J. Immunol., November 1, 2001; 167(9): 5092 - 5098. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Morita, H. K. Lee, H. Wang, H. Li, R. A. Mariuzza, and Y. Tanaka Structural Features of Nonpeptide Prenyl Pyrophosphates That Determine Their Antigenicity for Human {{gamma}}{{delta}} T Cells J. Immunol., July 1, 2001; 167(1): 36 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Miyagawa, Y. Tanaka, S. Yamashita, and N. Minato Essential Requirement of Antigen Presentation by Monocyte Lineage Cells for the Activation of Primary Human {{gamma}}{{delta}} T Cells by Aminobisphosphonate Antigen J. Immunol., May 1, 2001; 166(9): 5508 - 5514. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Altincicek, J. Moll, N. Campos, G. Foerster, E. Beck, J.-F. Hoeffler, C. Grosdemange-Billiard, M. Rodriguez-Concepcion, M. Rohmer, A. Boronat, et al. Cutting Edge: Human {{gamma}}{{delta}} T Cells Are Activated by Intermediates of the 2-C-methyl-D-erythritol 4-phosphate Pathway of Isoprenoid Biosynthesis J. Immunol., March 15, 2001; 166(6): 3655 - 3658. [Abstract] |